Banxia Gualou Xiebai Tang and Qishen Yiqi Dropping Pills Combined Therapy for Qi Deficiency, Phlegm, and Blood Stasis Syndrome in Post-PCI Coronary Heart Disease Patients.

Abstract

Objective: To evaluate the effects of Banxia Gualou Xiebai Tang combined with Qishen Yiqi Dropping Pills on Qi deficiency, phlegm, and blood stasis syndrome in post-percutaneous coronary intervention (PCI) coronary heart disease (CHD) patients.

Methods: A retrospective analysis was conducted on 100 post-PCI CHD patients with Qi deficiency, phlegm, and blood stasis syndrome treated from October 2022 to April 2024. Patients were divided into a control group (n=50, receiving standard secondary prevention) and an observation group (n=50, receiving additional Banxia Gualou Xiebai Tang and Qishen Yiqi Dropping Pills). Treatment efficacy, TCM syndrome scores, cardiac function (LVEF, LVEDD, LVESD, CO), blood lipids (TC, TG, HDL-C, LDL-C), hemorheological parameters (PV, Hct, HSBV, LSBV), and adverse events were compared.

Results: ① The total effective rate in the observation group (92.0%) was significantly higher than in the control group (76.0%) (P<0.05). ② TCM syndrome scores significantly improved in both groups, with greater improvement in the observation group at 3 and 6 months (P<0.05). ③ Cardiac function: LVEF and CO increased, while LVEDD and LVESD decreased in both groups, with more significant changes in the observation group (P<0.05). ④ Blood lipids: TC, TG, and LDL-C decreased, and HDL-C increased in both groups, with greater changes in the observation group (P<0.05). ⑤ Hemorheology: PV, Hct, HSBV, and LSBV decreased more in the observation group (P<0.05). ⑥ Adverse events: The observation group had a higher incidence of adverse events (22.0% vs 14.0%, P<0.05).

Conclusion: Banxia Gualou Xiebai Tang combined with Qishen Yiqi Dropping Pills, alongside standard treatment, significantly improves efficacy, cardiac function, hemorheology, and blood lipids in post-PCI CHD patients without increasing adverse events.